Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
WORCESTER, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced the closing of a Series A financing round. Nemucore plans to use the proceeds of the financing to advance NMI-900, a potential "best-in-class" therapeutic into a Phase 2b trial in ovarian cancer, the development and expansion of its innovative oncology pipeline and for general corporate purposes. Financial terms were not disclosed.
“We are pleased to close this financing, which is key to progressing our lead program into the next stage of clinical development,” said Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer and President of Nemucore. “This financing recognizes the capital efficiency of our organization, as we have successfully advanced novel therapies into the clinic for difficult-to-treat cancers. We believe the support of our investors is a strong endorsement of the leadership team and positions Nemucore’s assets for strategic growth and investment.”
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.nemucore.com.
Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 323-1717 [email protected] Jen LaVin (207) 360-0473 [email protected]
